Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Equity Ratio (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Equity Ratio for 7 consecutive years, with 0.72 as the latest value for Q1 2026.

  • For Q1 2026, Equity Ratio fell 11.48% year-over-year to 0.72; the TTM value through Mar 2026 reached 0.72, down 11.48%, while the annual FY2025 figure was 0.76, 6.87% down from the prior year.
  • Equity Ratio hit 0.72 in Q1 2026 for Barinthus Biotherapeutics, down from 0.76 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.9 in Q4 2022 and bottomed at 0.72 in Q1 2026.
  • Average Equity Ratio over 5 years is 0.84, with a median of 0.85 recorded in 2023.
  • Year-over-year, Equity Ratio soared 378.81% in 2022 and then decreased 11.48% in 2026.
  • Barinthus Biotherapeutics' Equity Ratio stood at 0.9 in 2022, then dropped by 3.15% to 0.87 in 2023, then dropped by 6.89% to 0.81 in 2024, then fell by 6.87% to 0.76 in 2025, then fell by 4.67% to 0.72 in 2026.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.72, 0.76, and 0.77 for Q1 2026, Q4 2025, and Q3 2025 respectively.